Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera
Metsera, founded in 2022, brings a pipeline of both oral and injectable treatments with different targets that could boost Pfizer's odds of entering the market.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
